Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

Nutrien sits on the higher end of the phosphate fertilizer cost curve, though this is by far its smallest business. Although it is a fully integrated phosphate producer, its cash costs of production ...

We believe EPAM is financially stable, with enough cash and access to debt to keep up the pace of internal innovation and inorganic expansion efforts, fueling future growth. EPAM had cash and cash ...